PRF's New Dawn: A Dual Bet on AI-Driven Solar and Advanced Eye Care

TEL AVIV, Israel – March 27, 2026 – PRF Technologies Ltd. (Nasdaq: PRFX) has signaled a dramatic corporate reinvention, capping a year of strategic acquisitions with a business update that paints a picture of a company reborn. Once focused on pain-reformulation therapeutics, PRF has aggressively pivoted into two of today's most dynamic high-tech sectors: AI-driven solar energy analytics and advanced ocular drug delivery. The company's year-end 2025 report reveals not just a new strategy but also significant early traction and a sharply improved financial outlook, positioning it as a unique, if complex, investment proposition.

A Strategic Overhaul into a Diversified Platform

2025 was a year of profound transformation for PRF. The company shed its singular focus and remade itself into what it calls a "diversified innovation platform." This new identity is built on two major strategic moves: the acquisition of AI analytics firm DeepSolar in March 2025 and a majority investment in the Boston-based medical device company LayerBio in August 2025.

This dual-pronged strategy moves PRF into the burgeoning markets of renewable energy optimization and next-generation ophthalmology. The company's leadership frames this as a deliberate move to create distinct but powerful value drivers.

Dr. Ehud Geller, Executive Chairman of PRF Technologies, commented on the shift in the company's official update, stating, “2025 was a transformational year for PRF as we repositioned the Company into a diversified innovation platform spanning healthcare and renewable-energy analytics... We believe these milestones position PRF with two distinct value drivers and multiple pathways to build long-term shareholder value.”

The strategy appears to be a calculated departure from its previous, high-cost clinical trial activities. By acquiring technologies with clearer paths to commercialization or later-stage development, PRF aims to leverage innovation while managing capital more efficiently.

A Clearer Vision for Post-Surgical Eye Care

The investment in LayerBio brought OcuRing™-K into PRF's portfolio, a technology that could disrupt the standard of care for one of the world's most common surgical procedures: cataract surgery. OcuRing™-K is a patented, bio-erodible intraocular ring designed to be implanted during surgery. It provides sustained, drop-less delivery of ketorolac, a non-steroidal anti-inflammatory drug (NSAID), to manage post-operative pain and inflammation.

The market need is significant. Post-cataract patients often face a complex and burdensome regimen of multiple daily eye drops, leading to poor compliance and inconsistent drug delivery. A single-application, sustained-release solution like OcuRing™-K offers a compelling advantage by improving patient convenience and potentially leading to better clinical outcomes.

PRF reported that OcuRing™-K has already demonstrated a favorable safety profile in preclinical studies and a Phase I clinical evaluation, with no serious adverse events observed. The company has completed the necessary activities to support an Investigational New Drug (IND) application for a planned Phase II study. Beyond OcuRing™-K, PRF has also highlighted the broader potential of LayerBio's platform technology, confirming it can be adapted to deliver other drugs like corticosteroids, opening the door for future applications in treating a range of ophthalmic conditions.

Navigating the regulatory pathway with the FDA and other global bodies will be a critical hurdle. Sustained-release implants face rigorous scrutiny over biocompatibility, predictable drug release profiles, and long-term safety. However, by targeting a well-understood procedure with a clear unmet need, PRF is betting on a streamlined development and adoption pathway.

DeepSolar's Ascent in a Competitive Energy Market

While the OcuRing™ platform matures, PRF's other new pillar, DeepSolar, is already making commercial inroads. Acquired in early 2025, DeepSolar has quickly progressed from a technology platform to a commercial business with a growing customer base. The platform uses AI-driven analytics to help owners and operators of utility-scale solar plants optimize performance, forecast energy production, and conduct technical due diligence.

The solar analytics market is competitive, with numerous players offering solutions for monitoring and management. DeepSolar aims to differentiate itself with a focus on actionable, ROI-driven insights for large-scale assets. Its offerings include "DeepSolar Predict," an AI forecasting module being developed with support from the prestigious NVIDIA Connect Program, which aims to improve weather forecast accuracy by up to 50%. Another key product is "Smart TDD," a specialized service for technical due diligence during asset commissioning, acquisition, or performance diagnosis.

This strategy is bearing fruit. DeepSolar has converted an initial pilot with Econergy at a 92 MW plant in Romania into a full commercial agreement. More significantly, it has secured a Software-as-a-Service (SaaS) contract with Shikun & Binui Energy, a major Independent Power Producer, for a 71 MW solar project, also in Romania. This provides a recurring revenue stream and a powerful endorsement. Adding to its momentum, DeepSolar recently secured its first due diligence engagement with EDF Power Solutions Israel, a subsidiary of the global energy giant EDF Group, further validating its specialized Smart TDD service.

A Financial Turnaround and the Road Ahead

This strategic pivot has been accompanied by a dramatic financial improvement. PRF reported a net loss of approximately $4.8 million for 2025, a stark contrast to the $14.6 million loss in 2024. The change is primarily due to a massive reduction in R&D expenses, which plummeted from $11.7 million to $1.1 million as costly clinical trials from its prior focus concluded.

The company ended 2025 with a stable balance sheet, holding approximately $4.1 million in cash and equivalents and maintaining positive working capital of around $1.9 million. This financial discipline, combined with $4.0 million raised through at-the-market offerings, has provided the capital to fuel its new dual-track strategy without taking on excessive debt.

However, the road ahead presents unique challenges. Managing two highly specialized, non-synergistic businesses requires a broad range of management expertise and careful allocation of resources. The company must prove to investors that it can maintain focus and execute effectively in both the highly regulated medical device space and the fast-moving renewable energy tech sector. Maintaining a coherent brand identity and investment thesis will be crucial as PRF continues to navigate its new, ambitious path. The company’s success will ultimately depend on its ability to turn the early promise of both OcuRing™-K and DeepSolar into sustained, long-term growth and profitability.